Observational studyAnnals of surgical oncology2026
Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study.
Observational study in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have become a viable treatment method for unresectable or recurrent esophageal squamous cell carcinoma (ESCC). However, the relationships between early tumor shrinkage (ETS) and clinical outcomes for ESCC patients receiving ICIs remain unknown. This observational study investigated the associations between ETS and clinical outcomes for patients with unresectable or recurrent ESCC who received ICIs.
methodsEarly tumor shrinkage was defined as the percentage decreases at the first evaluation, and the ETS cutoff value was 20%. Using an unbiased database of 128 unresectable or recurrent ESCC patients who received ICI plus chemotherapy or ICI plus ICI, this study evaluated the relationships between ETS and clinical outcomes by multivariable Cox proportional hazards regression models to adjust for potential confounders, including the clinical and pathologic features.
resultsAmong the patients, 52% had an ETS of 20% or more, and 48% had an ETS smaller than 20%. The ETS was not significantly associated with any of the clinical or pathologic features examined (all P > 0.09). However, ETS was significantly associated with longer progression-free survival (P < 0.01). Compared with the ETS-absent group, the multivariable-adjusted hazard ratio (HR) for the ETS-present group was 0.23 (95% confidence interval [Cl], 0.14-0.39; P < 0.01). Similarly, the same trend was observed for overall survival (multivariable-adjusted HR, 0.15; 95% CI, 0.07-0.31; P < 0.01). These prognostic associations of ETS were similarly observed in the ICI+chemotherapy and ICI+ICI groups (all P < 0.01).
conclusionsEarly tumor shrinkage was associated with favorable clinical outcomes for ICI-treated patients with unresectable or recurrent ESCC, providing a platform for further investigations of predictive markers and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.